Association of oxidative stress, insulin resistance, and diabetes risk phenotypes: The Framingham Offspring Study

Diabetes Care

Volumn 30, Issue 10, 2007, Pages 2529-2535

  Meigs, James B ^a   Larson, Martin G ^b   Fox, Caroline S ^c,d   Keaney Jr , John F ^e   Vasan, Ramachandran S ^c,f   Benjamin, Emelia J ^c,f  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Boston University   (United States)

^c FRAMINGHAM HEART STUDY   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^f BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; INSULIN; PROSTAGLANDIN;

ADULT; AGED; ARTICLE; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HEALTH HAZARD; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBESITY; OXIDATIVE STRESS; PHENOTYPE;

AGED; BIOLOGICAL MARKERS; BODY MASS INDEX; BODY SIZE; CARDIOVASCULAR DISEASES; CREATININE; DIABETES MELLITUS; DINOPROST; FEMALE; HEALTH SURVEYS; HUMANS; INSULIN RESISTANCE; MALE; MASSACHUSETTS; MIDDLE AGED; NUCLEAR FAMILY; OXIDATIVE STRESS; PHENOTYPE; PREDIABETIC STATE; PREVALENCE;

EID: 35148897217     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc07-0817     Document Type: Article

References (47)

1. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP: The continuing epidemics of obesity and diabetes in the United States. JAMA 286:1195-1200, 2001
2. Hanson RL, Imperatore G, Bennett PH, Knowler WC: Components of the "metabolic syndrome" and incidence of type 2 diabetes. Diabetes 51:3120-3127, 2002
3. Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G, the European Group of Insulin Resistance: Insulin resistance and hypersecretion in obesity. J Clin Invest 100:1166-1173, 1997
4. Keaney JF Jr, Larson MG, Vasan RS, Wilson PW, Lipinska I, Corey D, Massaro JM, Sutherland P, Vita JA, Benjamin EJ: Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 23:434-439, 2003
5. Houstis N, Rosen ED, Lander ES: Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 440:944-948, 2006
6. Gopaul NK, Anggard EE, Mallet AI, Betteridge DJ, Wolff SP, Nourooz-Zadeh J: Plasma 8-epi-PGF2 alpha levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Lett 368:225-229, 1995
7. Vijayalingam S, Parthiban A, Shanmugasundaram KR, Mohan V: Abnormal antioxidant status in impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Diabet Med 13:715-719, 1996
8. Urakawa H, Katsuki A, Sumida Y, Gabazza EC, Murashima S, Morioka K, Maruyama N, Kitagawa N, Tanaka T, Hori Y, Nakatani K, Yano Y, Adachi Y: Oxidative stress is associated with adiposity and insulin resistance in men. J Clin Endocrinol Metab 88:4673-4676, 2003
9. Gopaul NK, Manraj MD, Hebe A, Lee Kwai Yan S, Johnston A, Carrier MJ, Anggard EE: Oxidative stress could precede endothelial dysfunction and insulin resistance in Indian Mauritians with impaired glucose metabolism. Diabetologia 44:706-712, 2001
10. Yesilova Z, Yaman H, Oktenli C, Ozcan A, Uygun A, Cakir E, Sanisoglu SY, Erdil A, Ates Y, Aslan M, Musabak U, Erbil MK, Karaeren N, Dagalp K: Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 100:850-855, 2005
11. Sjogren P, Basu S, Rosell M, Silveira A, de Faire U, Vessby B, Hamsten A, Hellenius ML, Fisher RM: Measures of oxidized low-density lipoprotein and oxidative stress are not related and not elevated in otherwise healthy men with the metabolic syndrome. Arterioscler Thromb Vasc Biol 25:2580-2586, 2005
12. Couillard C, Ruel G, Archer WR, Pomerleau S, Bergeron J, Couture P, Lamarche B, Bergeron N: Circulating levels of oxidative stress markers and endothelial adhesion molecules in men with abdominal obesity. J Clin Endocrinol Metab 90:6454-6459, 2005
13. Shin MJ, Lee JH, Jang Y, Park E, Oh J, Chung JH, Chung N: Insulin resistance, adipokines, and oxidative stress in nondiabetic, hypercholesterolemic patients: leptin as an 8-epi-prostaglandin F2alpha determinant. Metabolism 55:918-922, 2006
14. Il'yasova D, Morrow JD, Wagenknecht LE: Urinary F2-isoprostanes are not associated with increased risk of type 2 diabetes. Obes Res 13:1638-1644, 2005
15. Boyne MS, Sargeant LA, Bennett FI, Wilks RJ, Cooper RS, Forrester TE: Isoprostanes, a marker of lipid peroxidation, may not be involved in the development of glucose intolerance. Diabetes Res Clin Pract 76:149-151, 2007
16. Roberts LJ 2nd, Morrow JD: The generation and actions of isoprostanes. Biochim Biophys Acta 1345:121-135, 1997
17. Eiserich JP, Baldus S, Brennan ML, Ma W, Zhang C, Tousson A, Castro L, Lusis AJ, Nauseef WM, White CR, Freeman BA: Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 296:2391-2394, 2002
18. Kannel WB, Feinleib M, McNamara JR, Garrison RJ, Castelli WP: An investigation of coronary heart disease in families: Framingham Offspring Study. Am J Epidemiol 110:281-290, 1979
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985
20. Balkau B, Charles MA, the European Group for the Study of Insulin Resistance (EGIR): Comment on the provisional report from the WHO consultation. Diabet Med 16:442-443, 1999
21. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 112:2735-2752, 2005
22. American Diabetes Association: The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26:3160-3167, 2003
23. Meigs JB, Cupples LA, Wilson PWF: Parental transmission of type 2 diabetes mellitus: the Framingham Offspring Study. Diabetes 49:2201-2207, 2000
24. Cupples LA, D'Agostino RB: Section 34: Some risk factors related to the annual incidence of cardiovascular disease and death using pooled repeated biennial measurements: Framingham Heart Study, 30-year followup. In The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease. Kannel W, Garrison R, Wolf P, Eds. Washington, DC, U.S. Department of Commerce, 1988
25. Meigs JB, Mittleman MA, Nathan DM, Tofler GH, Singer DE, Murphy-Sheehy PM, Lipinska I, D'Agostino RB, Wilson PWF: Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. J Am Med Assoc 283:221-228, 2000
26. SAS Institute: SAS/STAT User's Guide, Version 8. Cary, NC, SAS Institute, 1999
27. Meigs JB, Wilson PW, Fox CS, Vasan RS, Nathan DM, Sullivan L, D'Agostino RB: Body mass index, metabolic syndrome and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab 91:2906-2912, 2006
28. Hennig B, Meerarani P, Ramadass P, Watkins BA, Toborek M: Fatty acid-mediated activation of vascular endothelial cells. Metabolism 49:1006-1013, 2000
29. Griffin ME, Marcucci MJ, Cline GW, Bell K, Barucci N, Lee D, Goodyear LJ, Kraegen EW, White MF, Shulman GI: Free fatty acid-induced insulin resistance is associated with activation of protein kinase Cθ and alterations in the insulin signaling cascade. Diabetes 48:1270-1274, 1999
30. Evans JL, Goldfine ID, Maddux BA, Grodsky GM: Are oxidative stress-activated signaling pathways mediators of insulin resistance and β-cell dysfunction? Diabetes 52:1-8, 2003
31. Shulman GI: Cellular mechanisms of insulin resistance. J Clin Invest 106:171-176, 2000
32. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS: A central role for JNK in obesity and insulin resistance. Nature 420:333-336, 2002
33. Evans JL, Goldfine ID, Maddux BA, Grodsky GM: Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 23:599-622, 2002
34. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286:327-334, 2001
35. Hu FB, Meigs JB, Li TY, Rifai N, Manson JE: Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 53:693-700, 2004
36. Tripathy D, Mohanty P, Dhindsa S, Syed T, Ghanim H, Aljada A, Dandona P: Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 52:2882-2887
37. Stuhlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, Reaven GM, Tsao PS: Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 287:1420-1426, 2002
38. Cooke JP: Asymmetrical dimethylarginine: the Uber marker? Circulation 109:1813-1818, 2004
39. Arcaro G, Cretti A, Balzano S, Lechi A, Muggeo M, Bonora E, Bonadonna RC: Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation 105:576-582, 2002
40. Clark MG, Wallis MG, Barrett EJ, Vincent MA, Richards SM, Clerk LH, Rattigan S: Blood flow and muscle metabolism: a focus on insulin action. Am J Physiol Endocrinol Metab 284:E241-E258, 2003
41. Henstridge DC, Kingwell BA, Formosa MF, Drew BG, McConell GK, Duffy SJ: Effects of the nitric oxide donor, sodium nitroprusside, on resting leg glucose uptake in patients with type 2 diabetes. Diabetologia 48:2602-2608, 2005
42. Meigs JB, Wilson PWF, Tofler GH, Fox CS, Nathan DM, D'Agostino RB Sr, O'Donnell CJ: Markers of endothelial dysfunction predict incident type 2 diabetes (Abstract). Diabetes 54 (Suppl. 1):A90, 2005
43. Meigs JB, O'Donnell CJ, Tofler GH, Benjamin EJ, Fox CS, Lipinska I, Nathan DM, Sullivan LM, D'Agostino RB, Wilson PW: Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study. Diabetes 55:530-537, 2006
44. Rossi R, Cioni E, Nuzzo A, Origliani G, Modena MG: Endothelial-dependent vasodilation and incidence of type 2 diabetes in a population of healthy postmenopausal women. Diabetes Care 28:702-707, 2005
45. Vita JA, Brennan ML, Gokce N, Mann SA, Goormastic M, Shishehbor MH, Penn MS, Keaney JF Jr, Hazen SL: Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation 110:1134-1139, 2004
46. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Munzel T, Simoons ML, Hamm CW: Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 108:1440-1445, 2003
47. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, Goormastic M, Pepoy ML, McErlean ES, Topol EJ, Nissen SE, Hazen SL: Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 349:1595-1604, 2003